ASE values and 95% bootstrap confidence intervals for all estimators under all scenarios. حسب Mahmut Sami Erdoğan (22097195)

الموضوعات:

Numerical values underlying all Figs. حسب Juliana Zimmermann (10507091)

"…We tested this hypothesis in two multimodal brain imaging experiments in healthy humans, in which we drove large changes in total CBV by neuronal burst-suppression under anesthesia or by transient global vasodilation in a hypercapnic challenge. …"

Numeric values used to generate all the graphs presented in the figures. حسب Wenjia Yu (9422059)

الموضوعات:

ECoG timescales decrease during spatial attention. حسب Isabel Raposo (21615517)

"…<p><b>(A)</b> Top: behavioral timescales do not differ between different groups of participants (exp. 1 and 3/4) doing the same task; Bottom: Illustration of ECoG electrode placement for all subjects for both two location (left) and four location (right) tasks for the frontal, motor and parietal regions. …"

Ether Cleavage Decreases the Ion Exchange Capacity of Anion Exchange Membranes حسب Shakkira Erimban (6882539)

الموضوعات:

Ether Cleavage Decreases the Ion Exchange Capacity of Anion Exchange Membranes حسب Shakkira Erimban (6882539)

الموضوعات:

ActAs and CoT prompt strategies do not result in decreased error rate for tasks with increasing complexity. حسب Jacqueline A. Jansen (14894276)

Self-correction prompt strategy results in decreased error rate for all tasks with increasing complexity. حسب Jacqueline A. Jansen (14894276)

fileCont prompt strategy results in decreased error rate for some tasks with increasing complexity. حسب Jacqueline A. Jansen (14894276)

An increase in MOI decreases neuronal dendrite numbers. حسب Emily Z. Tabaie (16630841)

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Long-term anti-nucleocapsid response by baseline patient characteristics. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات: